← Back to Search

Algorithm-based recommendation for Risk Reduction

N/A
Waitlist Available
Led By Christopher F Chabris, PhD
Research Sponsored by National Bureau of Economic Research, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 months (between september 9, 2021 and april 30, 2022)
Awards & highlights

Study Summary

This trial will explore whether providing reasons that patients are considered high risk for flu complications increases the likelihood they will receive flu vaccine and decreases the likelihood that they receive diagnoses of flu and/or flu-like symptoms in the ensuing flu season.

Eligible Conditions
  • Risk Reduction
  • Influenza
  • Vaccinations
  • Health Promotion
  • Health Behaviors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~11 months (between september 9, 2021 and july 31, 2022)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 11 months (between september 9, 2021 and july 31, 2022) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Flu Vaccination at 2 Weeks After Final Outreach Date
Secondary outcome measures
Flu Complications
Flu Diagnosis
Flu Vaccination at 9 Weeks After Final Outreach Date
+1 more
Other outcome measures
Flu Vaccination at 2 Weeks After Final Outreach Date by Ethnicity
Flu Vaccination at 2 Weeks After Final Outreach Date by Gender
Flu Vaccination at 2 Weeks After Final Outreach Date by Race

Trial Design

5Treatment groups
Experimental Treatment
Active Control
Group I: Reminder ControlExperimental Treatment1 Intervention
Subjects in the reminder control arm will receive messages reminding them to get the flu shot without being advised of their risk status.
Group II: High Risk with Explanation Based on Medical RecordsExperimental Treatment3 Interventions
Subjects in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications via review of their medical records and will be provided a human-understandable short list of the top factors from their medical record that explain their risk.
Group III: High Risk with Explanation Based on AlgorithmExperimental Treatment4 Interventions
Subjects in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records by a computer algorithm and will be provided a human-understandable short list of the top factors from their medical record that explain their risk.
Group IV: High Risk OnlyExperimental Treatment2 Interventions
Subjects in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications, without specifying how or why the health system believes this to be the case.
Group V: No-Contact ControlActive Control1 Intervention
Subjects in the no-contact control arm will receive no additional pro-vaccination intervention beyond the health system's normal efforts. Although some patients are currently targeted for flu vaccination encouragement due to a conventional non-ML assessment that they are at high risk for complications, these patients are not told that they are at high risk or that they have been targeted.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Medical records-based recommendation
2020
N/A
~162710
Algorithm-based recommendation
2020
N/A
~162710
Reminder
2022
N/A
~311170
Risk reduction
2020
N/A
~162710

Find a Location

Who is running the clinical trial?

Massachusetts Institute of TechnologyOTHER
97 Previous Clinical Trials
12,684,926 Total Patients Enrolled
1 Trials studying Risk Reduction
40,671 Patients Enrolled for Risk Reduction
National Bureau of Economic Research, Inc.Lead Sponsor
31 Previous Clinical Trials
878,179 Total Patients Enrolled
1 Trials studying Risk Reduction
40,671 Patients Enrolled for Risk Reduction
Geisinger ClinicOTHER
149 Previous Clinical Trials
1,841,074 Total Patients Enrolled
3 Trials studying Risk Reduction
201,545 Patients Enrolled for Risk Reduction

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
2021. "Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05009251.
~12575 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top